Cargando…
Hemostatic phenotypes and genetic disorders
This review is focused on genetic regulators of bleeding and thrombosis with a focus on next‐generation sequencing (NGS) technologies for diagnosis and research of patients with inherited disorders. The molecular diagnosis of hemostatic phenotypes relies on the detection of genetic variants in the 9...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677882/ https://www.ncbi.nlm.nih.gov/pubmed/34964017 http://dx.doi.org/10.1002/rth2.12637 |
_version_ | 1784616234260627456 |
---|---|
author | Ver Donck, Fabienne Labarque, Veerle Freson, Kathleen |
author_facet | Ver Donck, Fabienne Labarque, Veerle Freson, Kathleen |
author_sort | Ver Donck, Fabienne |
collection | PubMed |
description | This review is focused on genetic regulators of bleeding and thrombosis with a focus on next‐generation sequencing (NGS) technologies for diagnosis and research of patients with inherited disorders. The molecular diagnosis of hemostatic phenotypes relies on the detection of genetic variants in the 99 curated disease‐causing genes implicated for bleeding, platelet, and thrombotic disorders through the use of multigene panel tests. In this review, we will provide an overview of the advantages and disadvantages of using such multigene panel tests for diagnostics. During the past decade, NGS technologies have also been used for the gene discovery of 32 novel genes involved in inherited hemostatic phenotypes. We will provide a brief overview of these genes and discuss what information (eg, linkage, consanguinity, multiple index cases with similar phenotypes, mouse models, and more) was used to support the gene discovery process. Next, we provide examples on how RNA sequencing is useful to explore disease mechanisms of novel and often unexpected genes. This review will summarize the important findings concerning NGS technologies for diagnostics and gene discovery that were presented at the ISTH 2021 conference. Finally, future perspectives in our field mainly deal with finding the needle in the haystack for some still unexplained patients and the need for exploring the noncoding gene space and rapid disease validation models. |
format | Online Article Text |
id | pubmed-8677882 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86778822021-12-27 Hemostatic phenotypes and genetic disorders Ver Donck, Fabienne Labarque, Veerle Freson, Kathleen Res Pract Thromb Haemost State of the Art Isth 2021 This review is focused on genetic regulators of bleeding and thrombosis with a focus on next‐generation sequencing (NGS) technologies for diagnosis and research of patients with inherited disorders. The molecular diagnosis of hemostatic phenotypes relies on the detection of genetic variants in the 99 curated disease‐causing genes implicated for bleeding, platelet, and thrombotic disorders through the use of multigene panel tests. In this review, we will provide an overview of the advantages and disadvantages of using such multigene panel tests for diagnostics. During the past decade, NGS technologies have also been used for the gene discovery of 32 novel genes involved in inherited hemostatic phenotypes. We will provide a brief overview of these genes and discuss what information (eg, linkage, consanguinity, multiple index cases with similar phenotypes, mouse models, and more) was used to support the gene discovery process. Next, we provide examples on how RNA sequencing is useful to explore disease mechanisms of novel and often unexpected genes. This review will summarize the important findings concerning NGS technologies for diagnostics and gene discovery that were presented at the ISTH 2021 conference. Finally, future perspectives in our field mainly deal with finding the needle in the haystack for some still unexplained patients and the need for exploring the noncoding gene space and rapid disease validation models. John Wiley and Sons Inc. 2021-12-16 /pmc/articles/PMC8677882/ /pubmed/34964017 http://dx.doi.org/10.1002/rth2.12637 Text en © 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | State of the Art Isth 2021 Ver Donck, Fabienne Labarque, Veerle Freson, Kathleen Hemostatic phenotypes and genetic disorders |
title | Hemostatic phenotypes and genetic disorders |
title_full | Hemostatic phenotypes and genetic disorders |
title_fullStr | Hemostatic phenotypes and genetic disorders |
title_full_unstemmed | Hemostatic phenotypes and genetic disorders |
title_short | Hemostatic phenotypes and genetic disorders |
title_sort | hemostatic phenotypes and genetic disorders |
topic | State of the Art Isth 2021 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677882/ https://www.ncbi.nlm.nih.gov/pubmed/34964017 http://dx.doi.org/10.1002/rth2.12637 |
work_keys_str_mv | AT verdonckfabienne hemostaticphenotypesandgeneticdisorders AT labarqueveerle hemostaticphenotypesandgeneticdisorders AT fresonkathleen hemostaticphenotypesandgeneticdisorders |